The Global Crisis of Parkinson’s Disease: Epidemiology and Risk Factors

Article Sidebar

22-Aug-5732.pdf
Published Aug 30, 2024
DOI: https://doi.org/10.18103/mra.v12i8.5732

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Safwaan Rana, BHSc
Ontario Tech University, Oshawa, Ontario, Canada.
Abdul Rehman M. Qureshi, MD Candidate, MSc
Khalifa University College of Medicine and Health Sciences, Abu Dhabi, UAE.
Zainab Sarfaraz, MBBS
Parkinson Clinic of Eastern Toronto and Movement Disorders Centre, Toronto, Ontario, Canada.
Yafiah Shakir, BSc Candidate
University of Toronto, Faculty of health sciences, Toronto, Canada.
Adnan Al-Sarawi, MBBS
King Fahad Hospital, Damam, Saudi Arabia.
Umar Siddique Muhammad, MD, CCFP, DABFM
Cedarbrae Medical Centre, Toronto, Ontario, Canada.
Mohamed Asadig Abounaja, MD, CCFP
Ellesmere Health Group, Toronto, Ontario, Canada.
Albert Akpalu, MD
Korle Bu Teaching Hospital, Greater Accra, Accra, Ghana.

Abstract

Parkinson’s disease is the second most prevalent neurodegenerative disorder, encompassing sufferers from all races worldwide. With countries around the world transitioning further along their demographics, many developing poor and middle-income countries are falling behind with the required healthcare, education and resources needed to meet the needs of Parkinson’s disease patients. We reviewed how demographic transition trends are affecting worldwide Parkinson’s disease incidence and prevalence, evaluated the effects of poverty on Parkinson’s disease management, reviewed current global initiatives to support Parkinson’s disease patients, and proposed factors for the prevention of Parkinson’s disease crises in the near future. Parkinson’s disease prevalence is increasing due to old age and higher life expectancy. North Americans have higher Parkinson’s disease prevalence than Asian and African populations. Parkinson’s disease is most prevalent amongst Caucasians in North American and European populations and amongst blacks in African populations. Important Parkinson’s disease risk factors include insecticide and heavy metal exposure, welding, antipsychotic medications, and LRRK2 gene mutations. The association of Parkinson’s disease and poverty showcases lack of knowledge of Parkinson’s disease diagnosis, predominance of care for more pervasive illnesses, limited healthcare facilities, inadequate or no access to care from specialists, and increases in Parkinson’s disease-related illnesses. Cost of care can lock up a significant portion of annual income since health insurance may not cover all expenses. These alarming situations may lead to a global Parkinson’s crisis. Thus, efforts need to be made to increase the number of training programs for educating caregivers, patients and Parkinson’s disease professionals to raise awareness and provide better healthcare and drug and treatment facilities.

Keywords: Epidemiology, Global Crisis, Parkinson’s Disease, Risk Factors

Article Details

How to Cite
RANA, Safwaan et al. The Global Crisis of Parkinson’s Disease: Epidemiology and Risk Factors. Medical Research Archives, [S.l.], v. 12, n. 8, aug. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5732>. Date accessed: 04 dec. 2024. doi: https://doi.org/10.18103/mra.v12i8.5732.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 12 No 8 (2024): Vol 12 No 8 (2024): August ISSUE, Issue 8, VOl.12
Section
Review Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Karlsen KH, Tandberg E, Årsland D, Larsen JP. Health related quality of life in Parkinson’s disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry. 2000;69:584–589.

2. Rana AQ, Ahmed US, Chaudry ZM, Vasan S. Parkinson's disease: a review of non-motor symptoms. Expert Rev Neurother. 2015;15(5):549-562.

3. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.

4. Muangpaisan W, Hori H, Brayne C. Systematic Review of the Prevalence and Incidence of Parkinson’s Disease in Asia. Epidemiology. 2009;19(6):281–293.

5. The World Bank. Global Economic Prospects: Having Fiscal Space and Using It. https://www.worldbank.org/content/dam/Worldbank/GEP/GEP2015a/pdfs/GEP15a_web_full.pdf. Published 2015. Accessed June 24, 2024.

6. Blanckenberg J, Bardien S, Glanzmann B, Okubadejo NU, Carr JA. The prevalence and genetics of Parkinson's disease in sub-Saharan Africans. Neurol Sci. 2013;335(1-2):22-25.

7. Cubo E, Doumbe J, Njiengwe E, et al. A Parkinson's disease tele-education program for health care providers in Cameroon. Neurol Sci. 2015;15:440-442.

8. Kotagal V, Bohnen NI, Müller ML, et al. Educational attainment and motor burden in Parkinson's disease. Mov Disord. 2015;30(8):1143-1147.

9. Okubadejo NU, Bower JH, Rocca WA, Maraganore DM. Parkinson’s disease in Africa: a systematic review of epidemiologic and genetic studies. Parkinsonism Relat Disord. 2006;21(12):2150-2156.

10. United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects: The 2015 Revision, World Population 2015 Wallchart. ST/ESA/SER.A/378. 2015.

11. African Development Bank Group Briefing Notes for ADB’s Long-Term Strategy Briefing Note 4: Africa’s Demographic Trends. http://www.afdb.org/fileadmin/uploads/afdb/Documents/Policy-Documents/FINAL%20Briefing%20Note%206%20Inclusive%20Growth.pdf. Published 2012. Accessed June 24, 2024.

12. Tan LCS, Venketasubramanian N, Hong CY, et al. Prevalence of Parkinson disease in Singapore. Neurology. 2004;62:231-238.

13. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol. 2011;26(1):1-58.

14. Willis AW, Evanoff BA, Lian M, et al. Metal emissions and urban incident Parkinson disease: a community health study of Medicare beneficiaries by using geographic information systems. Am J Epidemiol. 2010;172(12):1357-1363.

15. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013;80(22):2035-2041.

16. International Journal of Environmental Research and Public Health. Environmental Exposures and Parkinson’s Disease. https://www.mdpi.com/1660-4601/13/3/377. Accessed June 24, 2024.

17. Cannon JR, Greenamyre JT. The role of environmental exposures in neurodegeneration and neurodegenerative diseases. Toxicol Sci. 2011;124(2):225-250.

18. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302(5646):819-822.

19. Bowler RM, Koller W, Schulz PE. Parkinsonism due to manganism in a welder: neurological and neuropsychological sequelae. Neurotoxicology. 2006;27(3):327–332.

20. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT, Swanson PD, Checkoway H. Parkinson’s disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology. 2003;60(11):1761-1766.

21. Racette BA, McGee-Minnich L, Moerlein SM, et al. Welding related Parkinsonism: clinical features, treatment, and pathophysiology. Neurology. 2001;56(1):8–13.

22. Sabitu K, Iliyasu Z, Dauda M. Awareness of occupational hazards and utilization of safety measures among welders in Kaduna metropolis, northern Nigeria. Ann Afr Med. 2009;8(1):46-51.

23. Qin J, Liu W, Zhu J, et al. Health related quality of life and influencing factors among welders. PLoS One. 2014;9(7)

24. Punia S, Behari M, Govindappa ST, et al. Absence/rarity of commonly reported LRRK2 mutations in Indian Parkinson's disease patients. Neurosci Lett. 2006;409(2):83-88.

25. World Health Organization. Atlas: Country Resources for Neurological Disorders. 2004;28–29.

26. Racette BA, Willis AW. Time to change the blind men and the elephant approach to Parkinson disease. Neurology. 2015;85(2):190-196.

27. Ragothaman M, Murgod UA, Gururaj G, et al. High occurrence and low recognition of Parkinsonism (and possible PD) in old age homes in Bangalore, South India. J Assoc Physicians India. 2008;56:233-236.

28. Sahn DE, Stifel DC. Poverty Comparisons Over Time and Across Countries in Africa. World Dev. 2000;28:2123-2155.

29. Sandoval DA, Rank MR, Hirschl TA. The Increasing Risk of Poverty across the American Life Course. Demography. 2009;46:717-737.

30. Drummond D, Capeluck E. Long-term Fiscal and Economic Projections for Canada and the Provinces and Territories 2014-2038. CSLS Res Rep. 2015;1-66.

31. Fouarge D, Layte R. Welfare regimes and poverty dynamics: the duration and recurrence of poverty spells in Europe. Soc Policy. 2005;34:407-426.

32. Cilia R, Akpalu A, Cham M, et al. Parkinson’s disease in sub-Saharan Africa: step-by-step into the challenge. Neurodegener Dis Manag. 2011;128(3):1-8.

33. Deeb J, Shah M, Muhammed N, et al. A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM. 2010;hcq142.

34. Kumari U, Tan EK. LRRK2 in Parkinson’s disease: genetic and clinical studies from patients. FEBS J. 2009;276(22):6455-6463.

35. Ragothaman M, Govindappa ST, Rattihalli R, Subbakrishna DK, Muthane UB. Direct costs of managing Parkinson’s disease in India: concerns in a developing country. Mov Disord. 2006;21(10): 1755-1758.

36. Rektorova I, Rascol O, Volkmann J, et al. The European Parkinson’s disease standards of care consensus statement. Mov Disord. 2011;1:4-14.

37. Dodel R, Reese JP, Balzer M, Oertel WH. The economic burden of Parkinson’s disease. Eur Neurol Rev. 2008;3(2):11-14.

38. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Burden of parkinsonism: a population-based study. Mov Disord. 2003;18:313-319.

39. Daneault JF, Carignan B, Sadikot AF, Panisset M, Duval C. Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia? BMC Med. 2013;11:76.